Bio-Reference Laboratories (BRLI) 27.20 $BRLI
Bio-Reference Laboratories, Inc. Announces That Robert Daber, Ph.D. Will Join Company as Director of R&D and Cancer Genetics
GlobeNewswire - Wed Apr 16, 7:30AM CDT
Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announced today that it has hired Robert Daber, Ph.D. to assume the dual role as Director of Research and Development and Director of Cancer Genetics at its Elmwood Park international headquarters. BRLI has been an industry leader in clinical diagnostics primarily as a result of its ongoing development of innovative testing based on new and emerging technology. Dr. Daber will take over leadership of this pioneering process along with his directorship of the cancer genetics program at BRLI.
Clinical Laboratory Services Market 2013-2018: Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Apr 15, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98zpd/clinical) has announced the addition of the "Clinical Laboratory Services - Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles" report to their offering. The Clinical Laboratory Services estimates the market at $99.1 billion for 2013, up 1.3% from the estimated value in 2008 of $92.7 billion. Faced with daunting reimbursement cuts and other challenges, the world market for clinical laboratory services grew just over one percent in the past five year. The report notes that while there are a number of drivers for this market: aging populations, a growing incidence of chronic diseases, increasing emphasis on diagnosis and disease monitoring, and a growth in advanced testing technologies and practices. However, there are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions, and these are dampening growth. In the United States, the U.S. Congress ultimately has the responsibility to adjust the Medicare fee schedule according to economic factors, including controlling costs, monitoring utilization, and ensuring adequate delivery of health care services. The passing of the Patient Protection and Affordable Care Act generated a number of provisions on laboratory fee schedules, mostly in the direction of reductions. These reductions were effective starting 2011 and will continue to be adjusted through 2015. Medicare has slashed reimbursement amounts for many common tests such as Vitamin B12, triglycerides and glucose nearly six percent between 2009 and 2013. Some tests, such as total iron or aluminum tests have been cut 19% and 30% respectively during that period. Bio-Reference Laboratories, Quest, Lab Corp, Myriad, and Spectra are among the leaders in the industry. Quest Diagnostics and LabCorp have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. Smaller, independent laboratories may find it difficult to keep up with the fast changing industry largely due to limited financial abilities to invest in new technologies and testing services. Some laboratories, such as Bio-Reference Labs have found success in operating on a regional basis while companies such as Myriad Genetics and Genomic Health remain competitive by focusing on more specialized genetic-based testing. Key Topics Covered: 1. Executive Summary 2. Industry Overview 3. CLIA Laboratory Registration, Laboratories By Type 4. Leading Market Participants 5. Market Trends And Summary Companies Mentioned - Bio-Reference Laboratories - Clarient, Inc. - DaVita - Genomic Health - Genoptix, Inc. - Genzyme Corporation - Laboratory Corporation of America (LabCorp) - Quest Diagnostics, Inc. - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/d98zpd/clinical
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
Myriad Genetics Jumps on Medicare Decision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 1:50PM CDT
Shares of Myriad Genetics gained 11.47% on yesterday's close.
3 Stocks Rising on Unusual Volume
at The Street - Thu Mar 27, 8:09AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Bio-Reference Labs Has Returned 11.3% Since SmarTrend Recommendation (BRLI)
Comtex SmarTrend(R) - Fri Mar 14, 9:59AM CDT
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.67. In approximately 4 months, Bio-Reference Labs has returned 11.31% as of today's recent price of $26.32.
Myriad Stock Tumbles After Court Allows Rival To Sell
at Investor's Business Daily - Tue Mar 11, 10:18AM CDT
Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for...
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Bio-Reference Laboratories (BRLI) Falls: Stock Goes Down 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:42AM CST
Bio-Reference Laboratories saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 5% on the day.
Bio-Reference Laboratories, Inc. Reports Revenue Growth Despite Reimbursement Pressure and Impactful Weather
GlobeNewswire - Tue Mar 04, 7:31AM CST
Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announces record first quarter results for revenues. Except for per share data or where otherwise noted, numbers are in thousands.
Bio-Reference Labs Shares Down 13.4% Since SmarTrend's Sell Call (BRLI)
Comtex SmarTrend(R) - Thu Feb 27, 9:59AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 3 months, Bio-Reference Labs has returned 13.36% as of today's recent price of $25.71.
BioReference Laboratories, Inc. Announces Earnings Date for First Quarter Fiscal Year 2014
GlobeNewswire - Tue Feb 25, 9:25AM CST
BioReference Laboratories, Inc. (Nasdaq:BRLI) announced today it plans to issue earnings results for the first quarter 2014 before the open of market trading on Tuesday, March 4, 2014. The Company's earnings conference call is to take place the same day at 10:30 a.m. EST. The call will be hosted by Marc D. Grodman M.D., President and Chief Executive Officer.
Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019
M2 - Tue Feb 25, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/zt5xj4/clinical) has announced the addition of the "Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019" report to their offering. The clinical diagnostic tests performed by laboratories can be broadly classified into four major categories, namely, clinical chemistry, medical microbiology & cytology, human and tumour genetics and other esoteric tests. Ranging from routine blood and urine tests to high-end genetic analysis including fluorescence in situ hybridization (FISH), molecular expression testing etc., clinical laboratories offer numerous tests that help detect disease progression and abnormalities. The three major types of service providers in this market include hospital-based laboratories, clinic-based laboratories and stand-alone laboratories. The global market for clinical laboratory services is expected to record a CAGR of 5.8% during the forecast period of 2013 to 2019, to grow from a USD 162.71 billion market in 2012 to a USD 241.37 billion market in 2019. With the increasing incidence rates of debilitating conditions such as cancer, diabetes and infectious diseases, the number of patients that will opt for such tests will continue to increase in the future and thereby increase the demand for these services. Moreover, the percentage of aged population in the U.S. is expected to grow to an estimated 20% by 2030. Such a large population of elderly people in the U.S. alone will lead to high testing volumes for clinical laboratories. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Clinical Laboratory Services Market, By Test Type, 2011 - 2019 (USD Billion) 5 Global Clinical Laboratory Services Market, By Service Provider, 2011 - 2019 (USD Billion) 6 Global Clinical Laboratory Services Market, By Geography, 2011 - 2019 (USD Billion) 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - ARUP Laboratories - Abbott Laboratories - Bio-Reference Laboratories - Bioscientia Healthcare - Charles River Laboratories - Genoptix Medical Laboratory - Healthscope Ltd - Labco SA - Laboratory Corporation Of America Holdings (Labcorp) - Quest Diagnostics, Inc - Sonic Healthcare Limited - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/zt5xj4/clinical
Downtrend Call Working As Bio-Reference Labs Stock Falls 11.9% (BRLI)
Comtex SmarTrend(R) - Mon Feb 10, 9:33AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 2 months, Bio-Reference Labs has returned 11.88% as of today's recent price of $26.15.
New Research Centre to Help Injured, Ill and Disabled Workers Stay in Job Market
Marketwire Canada - Tue Feb 04, 3:00AM CST
Vancouver-based Krystal Johnston, 29, has carpal tunnel syndrome. Two surgeries, one on each wrist, failed to fix the loss of feeling in her hands and arms.
Bio-Reference Labs Down 17.2% Since SmarTrend Downtrend Call (BRLI)
Comtex SmarTrend(R) - Tue Jan 14, 5:27PM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 2 months, Bio-Reference Labs has returned 17.20% as of today's recent price of $24.57.
Quest Diagnostics Inc.: Does This Unloved Company Deserve Your Attention
Cory Renauer, The Motley Fool - Motley Fool - Thu Jan 09, 12:19PM CST
After nearly two years of flat to falling revenue, it's just plain difficult for Quest Diagnostics to get any positive attention, especially with the black cloud of reimbursement uncertainty hanging over its industry. To end the year, shares of...
Bio-Reference Laboratories, Inc. Announces That Robert Daber, Ph.D. Will Join Company as Director of R&D and Cancer Genetics
GlobeNewswire - Wed Apr 16, 7:30AM CDT
Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announced today that it has hired Robert Daber, Ph.D. to assume the dual role as Director of Research and Development and Director of Cancer Genetics at its Elmwood Park international headquarters. BRLI has been an industry leader in clinical diagnostics primarily as a result of its ongoing development of innovative testing based on new and emerging technology. Dr. Daber will take over leadership of this pioneering process along with his directorship of the cancer genetics program at BRLI.
Clinical Laboratory Services Market 2013-2018: Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Apr 15, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98zpd/clinical) has announced the addition of the "Clinical Laboratory Services - Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles" report to their offering. The Clinical Laboratory Services estimates the market at $99.1 billion for 2013, up 1.3% from the estimated value in 2008 of $92.7 billion. Faced with daunting reimbursement cuts and other challenges, the world market for clinical laboratory services grew just over one percent in the past five year. The report notes that while there are a number of drivers for this market: aging populations, a growing incidence of chronic diseases, increasing emphasis on diagnosis and disease monitoring, and a growth in advanced testing technologies and practices. However, there are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions, and these are dampening growth. In the United States, the U.S. Congress ultimately has the responsibility to adjust the Medicare fee schedule according to economic factors, including controlling costs, monitoring utilization, and ensuring adequate delivery of health care services. The passing of the Patient Protection and Affordable Care Act generated a number of provisions on laboratory fee schedules, mostly in the direction of reductions. These reductions were effective starting 2011 and will continue to be adjusted through 2015. Medicare has slashed reimbursement amounts for many common tests such as Vitamin B12, triglycerides and glucose nearly six percent between 2009 and 2013. Some tests, such as total iron or aluminum tests have been cut 19% and 30% respectively during that period. Bio-Reference Laboratories, Quest, Lab Corp, Myriad, and Spectra are among the leaders in the industry. Quest Diagnostics and LabCorp have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. Smaller, independent laboratories may find it difficult to keep up with the fast changing industry largely due to limited financial abilities to invest in new technologies and testing services. Some laboratories, such as Bio-Reference Labs have found success in operating on a regional basis while companies such as Myriad Genetics and Genomic Health remain competitive by focusing on more specialized genetic-based testing. Key Topics Covered: 1. Executive Summary 2. Industry Overview 3. CLIA Laboratory Registration, Laboratories By Type 4. Leading Market Participants 5. Market Trends And Summary Companies Mentioned - Bio-Reference Laboratories - Clarient, Inc. - DaVita - Genomic Health - Genoptix, Inc. - Genzyme Corporation - Laboratory Corporation of America (LabCorp) - Quest Diagnostics, Inc. - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/d98zpd/clinical
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
Myriad Genetics Jumps on Medicare Decision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 1:50PM CDT
Shares of Myriad Genetics gained 11.47% on yesterday's close.
3 Stocks Rising on Unusual Volume
at The Street - Thu Mar 27, 8:09AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Bio-Reference Labs Has Returned 11.3% Since SmarTrend Recommendation (BRLI)
Comtex SmarTrend(R) - Fri Mar 14, 9:59AM CDT
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.67. In approximately 4 months, Bio-Reference Labs has returned 11.31% as of today's recent price of $26.32.
Myriad Stock Tumbles After Court Allows Rival To Sell
at Investor's Business Daily - Tue Mar 11, 10:18AM CDT
Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for...
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Bio-Reference Laboratories (BRLI) Falls: Stock Goes Down 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:42AM CST
Bio-Reference Laboratories saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 5% on the day.
Bio-Reference Laboratories, Inc. Reports Revenue Growth Despite Reimbursement Pressure and Impactful Weather
GlobeNewswire - Tue Mar 04, 7:31AM CST
Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announces record first quarter results for revenues. Except for per share data or where otherwise noted, numbers are in thousands.
Bio-Reference Labs Shares Down 13.4% Since SmarTrend's Sell Call (BRLI)
Comtex SmarTrend(R) - Thu Feb 27, 9:59AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 3 months, Bio-Reference Labs has returned 13.36% as of today's recent price of $25.71.
BioReference Laboratories, Inc. Announces Earnings Date for First Quarter Fiscal Year 2014
GlobeNewswire - Tue Feb 25, 9:25AM CST
BioReference Laboratories, Inc. (Nasdaq:BRLI) announced today it plans to issue earnings results for the first quarter 2014 before the open of market trading on Tuesday, March 4, 2014. The Company's earnings conference call is to take place the same day at 10:30 a.m. EST. The call will be hosted by Marc D. Grodman M.D., President and Chief Executive Officer.
Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019
M2 - Tue Feb 25, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/zt5xj4/clinical) has announced the addition of the "Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019" report to their offering. The clinical diagnostic tests performed by laboratories can be broadly classified into four major categories, namely, clinical chemistry, medical microbiology & cytology, human and tumour genetics and other esoteric tests. Ranging from routine blood and urine tests to high-end genetic analysis including fluorescence in situ hybridization (FISH), molecular expression testing etc., clinical laboratories offer numerous tests that help detect disease progression and abnormalities. The three major types of service providers in this market include hospital-based laboratories, clinic-based laboratories and stand-alone laboratories. The global market for clinical laboratory services is expected to record a CAGR of 5.8% during the forecast period of 2013 to 2019, to grow from a USD 162.71 billion market in 2012 to a USD 241.37 billion market in 2019. With the increasing incidence rates of debilitating conditions such as cancer, diabetes and infectious diseases, the number of patients that will opt for such tests will continue to increase in the future and thereby increase the demand for these services. Moreover, the percentage of aged population in the U.S. is expected to grow to an estimated 20% by 2030. Such a large population of elderly people in the U.S. alone will lead to high testing volumes for clinical laboratories. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Clinical Laboratory Services Market, By Test Type, 2011 - 2019 (USD Billion) 5 Global Clinical Laboratory Services Market, By Service Provider, 2011 - 2019 (USD Billion) 6 Global Clinical Laboratory Services Market, By Geography, 2011 - 2019 (USD Billion) 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - ARUP Laboratories - Abbott Laboratories - Bio-Reference Laboratories - Bioscientia Healthcare - Charles River Laboratories - Genoptix Medical Laboratory - Healthscope Ltd - Labco SA - Laboratory Corporation Of America Holdings (Labcorp) - Quest Diagnostics, Inc - Sonic Healthcare Limited - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/zt5xj4/clinical
Downtrend Call Working As Bio-Reference Labs Stock Falls 11.9% (BRLI)
Comtex SmarTrend(R) - Mon Feb 10, 9:33AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 2 months, Bio-Reference Labs has returned 11.88% as of today's recent price of $26.15.
New Research Centre to Help Injured, Ill and Disabled Workers Stay in Job Market
Marketwire Canada - Tue Feb 04, 3:00AM CST
Vancouver-based Krystal Johnston, 29, has carpal tunnel syndrome. Two surgeries, one on each wrist, failed to fix the loss of feeling in her hands and arms.
Bio-Reference Labs Down 17.2% Since SmarTrend Downtrend Call (BRLI)
Comtex SmarTrend(R) - Tue Jan 14, 5:27PM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 2 months, Bio-Reference Labs has returned 17.20% as of today's recent price of $24.57.
Quest Diagnostics Inc.: Does This Unloved Company Deserve Your Attention
Cory Renauer, The Motley Fool - Motley Fool - Thu Jan 09, 12:19PM CST
After nearly two years of flat to falling revenue, it's just plain difficult for Quest Diagnostics to get any positive attention, especially with the black cloud of reimbursement uncertainty hanging over its industry. To end the year, shares of...
